Nymox Pharmaceutical Corporation EBITDA | NYMX

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Nymox Pharmaceutical Corporation

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-4.28 M	-8.35 M	-6.65 M	-12.5 M	-11.7 M	-13.3 M	-10.6 M	-13.2 M	-12.9 M	-17.7 M	-4.72 M	-4.88 M	-7.58 M	-9.61 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-4.28 M	-17.7 M	-9.86 M

Quarterly EBITDA Nymox Pharmaceutical Corporation

2024-Q4	2024-Q3	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-4.28 M	-	-8.35 M	-	-	-	-	-	-	-	-	-3.29 M	-3.98 M	-2.43 M	-	-4.14 M	-2.93 M	-2.63 M	-	-2.51 M	-5.2 M	-2.91 M	-	-2.81 M	-2.42 M	-2.66 M	-	-4.57 M	-2.6 M	-2.76 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-2.42 M	-8.35 M	-3.56 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Aclaris Therapeutics ACRS	-75.9 M	$ 5.32	0.09 %	$ 652 M	USA
ADC Therapeutics SA ADCT	-121 M	$ 1.05	0.46 %	$ 133 M	Schweiz
Agenus AGEN	-10.2 M	$ 7.21	0.7 %	$ 214 M	USA
Фармсинтез LIFE	-22.6 M	-	-	-	Russia
Akebia Therapeutics AKBA	24.8 M	$ 0.92	1.64 %	$ 237 M	USA
Alector ALEC	-150 M	$ 1.93	0.81 %	$ 199 M	USA
Amryt Pharma plc AMYT	-38.6 M	-	-	$ 621 M	Britain
Aligos Therapeutics ALGS	-87.1 M	$ 5.05	1.2 %	$ 49.9 M	USA
Alkermes plc ALKS	281 M	$ 46.07	0.09 %	$ 7.59 B	Irlanda
Allogene Therapeutics ALLO	-197 M	$ 1.69	0.58 %	$ 373 M	USA
Alnylam Pharmaceuticals ALNY	557 M	$ 239.36	0.46 %	$ 31.4 B	USA
Altimmune ALT	-94.4 M	$ 3.24	0.31 %	$ 285 M	USA
ALX Oncology Holdings ALXO	-103 M	$ 1.76	0.53 %	$ 94.4 M	USA
Evelo Biosciences EVLO	-106 M	-	-14.46 %	$ 27.9 M	USA
Amphastar Pharmaceuticals AMPH	172 M	$ 23.95	1.31 %	$ 1.12 B	USA
AnaptysBio ANAB	48.5 M	$ 54.31	0.15 %	$ 1.56 B	USA
Anika Therapeutics ANIK	-5.68 M	$ 20.84	0.24 %	$ 299 M	USA
ANI Pharmaceuticals ANIP	203 M	$ 73.59	2.05 %	$ 1.48 B	USA
Aptevo Therapeutics APVO	-26.1 M	$ 1.72	0.58 %	$ 543 K	USA
Allakos ALLK	-115 M	-	-	$ 28.6 M	USA
Aquestive Therapeutics AQST	-70.5 M	$ 4.82	0.21 %	$ 515 M	USA
Arcturus Therapeutics Holdings ARCT	-73.2 M	$ 15.6	0.25 %	$ 427 M	Israel
Armata Pharmaceuticals ARMP	-35.1 M	$ 4.07	2.21 %	$ 147 M	USA
Assembly Biosciences ASMB	-12 M	$ 25.48	0.54 %	$ 286 M	USA
Actinium Pharmaceuticals ATNM	-36.1 M	$ 1.24	0.79 %	$ 38.7 M	USA
AbbVie ABBV	15.8 B	$ 262.51	0.01 %	$ 464 B	USA
Atara Biotherapeutics ATRA	38 M	$ 10.11	7.1 %	$ 127 M	USA
Aurinia Pharmaceuticals AUPH	52.7 M	$ 16.96	5.15 %	$ 2.28 B	Canada
Autolus Therapeutics plc AUTL	-262 M	$ 1.87	0.53 %	$ 498 M	Britain
Atea Pharmaceuticals AVIR	-180 M	$ 5.15	1.24 %	$ 420 M	USA
Axon Enterprise AXON	21.1 M	$ 468.42	5.96 %	$ 36.6 B	USA
Axsome Therapeutics AXSM	-166 M	$ 211.97	3.87 %	$ 10.5 B	USA
Aytu BioScience AYTU	-2.45 M	$ 1.97	0.5 %	$ 12.4 M	USA
BridgeBio Pharma BBIO	-518 M	$ 68.3	0.1 %	$ 13.1 B	USA
Bicycle Therapeutics plc BCYC	-241 M	$ 3.64	0.68 %	$ 252 M	Britain
Black Diamond Therapeutics BDTX	12.8 M	$ 1.94	1.02 %	$ 110 M	USA
Beam Therapeutics BEAM	-361 M	$ 23.1	0.15 %	$ 2.28 B	USA
Biogen BIIB	780 M	$ 216.01	0.42 %	$ 31.6 B	USA
BioLineRx Ltd. BLRX	-10.3 M	$ 2.48	0.79 %	$ 6.11 B	Israel
AbCellera Biologics ABCL	-199 M	$ 11.67	2.28 %	$ 3.49 B	Canada
Benitec Biopharma BNTC	-51.1 M	$ 11.04	0.9 %	$ 514 M	USA
Checkmate Pharmaceuticals CMPI	-61.4 M	-	-	$ 231 M	USA
Burford Capital Limited BUR	232 M	$ 3.87	0.8 %	$ 848 M	Britain
Clovis Oncology CLVS	-44.2 M	-	-7.23 %	$ 13 M	USA
Chimerix CMRX	-96.5 M	-	-	$ 756 M	USA
Concert Pharmaceuticals CNCE	-76 M	-	-	$ 401 M	USA
Cabaletta Bio CABA	-171 M	$ 2.49	0.39 %	$ 250 M	USA
Can-Fite BioPharma Ltd. CANF	-9.93 M	$ 2.24	0.89 %	$ 3.69 M	Israel
Catalyst Biosciences CBIO	14 M	$ 17.18	1.7 %	$ 1.53 B	USA
C4 Therapeutics CCCC	-113 M	$ 3.45	0.58 %	$ 286 M	USA